MS
Vice President, Science Policy
Get the full picture
Sign in to uncover key details.
friendsofcancerresearch.org
Non-Profit & Charitable Organizations · District of Columbia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1800 M St NW Ste 1050, Washington, Distr...Phone Number
(202) 944-6700Revenue
<$5 MillionIndustry
About friendsofcancerresearch.org
Friends of Cancer Research is a non-profit organization dedicated to advancing science and policy with the goal of speeding life-saving treatments to cancer patients. They collaborate with healthcare partners to drive initiatives in drug and diagnostic development, as well as policy research. Their projects include the ctMoniTR project and the Homologous Recombination Deficiency Harmonization Project, focused on improving treatment decision-making. The organization emphasizes the incorporation of patient voices in research and aims to increase access to clinical trials.Explore more
friendsofcancerresearch.org Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
friendsofcancerresearch.org Tech Stack
A closer look at the technologies used by friendsofcancerresearch.org
See more technologies
Top Non-Profit & Charitable Organizations Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding friendsofcancerresearch.org
Sign Up For FreeTo access detailed company insights
Friends of Cancer Research is a non-profit organization dedicated to advancing science and policy with the goal of speeding life-saving treatments to cancer patients. They collaborate with healthcare partners to drive initiatives in drug and diagnostic development, as well as policy research. Their projects include the ctMoniTR project and the Homo... Read More
